About
Explore Cell Therapies

About Cell Therapies

Our Facility

View our Services

Partnerships and Collaborations

Careers at Cell Therapies

Contact us

Since 2003, Cell Therapies has manufactured cell therapies, ex vivo gene therapies, and regenerative medicine products under GMP standards to meet global regulatory requirements.

Learn about Cell Therapies
Services
Explore Services

Contract Manufacturing

Technology Transfer

Process Development

Analytical Testing and Development

Quality as a Service

Consulting and Advisory

Clinical Trial Support

Cryopreservation & Logistics

Digitalization & Automation

With over two decades of experience in GMP manufacturing of cell-based products, Cell Therapies is a trusted partner in transforming promising research into scalable, compliant, and commercially viable therapies.

Learn about Our Services
Facility
Careers
Explore Careers

Careers at Cell Therapies

View Current Opportunities

Upload your Resume

We are always on the lookout for curious minds, problem-solvers, and biotech enthusiasts to join our team. If you have a background in GMP manufacturing, QC, QA, engineering, or cell and gene therapy development, we would love to hear from you.

Find out about a career at Cell Therapies
News and Resources
Explore News and Resources

All News and Resources

News

Resources

Filter
All News
Resources

The Australian Advantage
The Australian Advantage
Read More

First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial
First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial
Read More

Arovella IND Acceptance for iNKT Cell Therapy Platform
Arovella IND Acceptance for iNKT Cell Therapy Platform
Read More

Read the latest from Cell Therapies
Contact

News

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration

Cell Therapies Pty Ltd (Cell Therapies) and Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) have…

Cell TherapiesJuly 16, 2025

Resources

Technology Transfers for CGT products: Understanding what is needed for success

Transferring a cell and gene therapy (CGT) product from development to manufacturing involves a detailed…

Cell TherapiesJune 20, 2024

News

CTPL to be AdAlta’s preferred manufacturer of immunotherapies

Cell Therapies Pty Ltd to be preferred manufacturer of cellular immunotherapies Establishes key partnership to…

Cell TherapiesMay 12, 2024

Resources

Quality Assurance: The Importance of Robust Investigations

Quality Assurance: The Importance of Robust Investigations Quality Assurance (QA) is a broad process that…

Cell TherapiesApril 22, 2024

Resources

Ensuring Every Batch is a Success: Validation and Qualification

Ensuring Every Batch is a Success: Validation and Qualification in Cell and Gene Therapy Manufacturing…

Cell TherapiesMarch 10, 2024

Resources

Translating research discoveries to commercialised cell and gene therapy products; asking the right questions as an academic.

When translating research discoveries in the cell and gene therapy sector, numerous considerations must be…

Cell TherapiesNovember 28, 2023

News

Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials

Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing…

Cell TherapiesNovember 8, 2023

Resources

From Concept to Commercialisation: Why the selection of an organisation for a cell and gene therapies can impact your patient outcomes and competitive advantage

The development pipeline of cell and gene therapies faces numerous obstacles while striving for the…

Cell TherapiesAugust 14, 2023

News

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Bev Menner as the company’s new Chief Executive Officer.

Cell Therapies Pty Ltd, a leading provider of cell and gene therapy products in the…

Cell TherapiesJuly 26, 2023

News

New commercial-scale cell and gene therapy manufacturing facility for APAC market supply

Cell Therapies Pty Ltd. is excited to announce the opening of new cell and gene…

Cell TherapiesJuly 25, 2023

Resources

Translating innovative cell therapies: What is GMP?

The cell therapy sector is growing rapidly and within it, cell-based therapies derived from human…

Cell TherapiesMay 22, 2023

Resources

Why Australia should be your choice for CGT development

The development of cell and gene therapy is rapidly growing in our industry with a…

Cell TherapiesFebruary 22, 2023

Filter

The Australian Advantage

First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial

Arovella IND Acceptance for iNKT Cell Therapy Platform

Cell Therapies

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration

Technology Transfers for CGT products: Understanding what is needed for success

CTPL to be AdAlta’s preferred manufacturer of immunotherapies

Quality Assurance: The Importance of Robust Investigations

Ensuring Every Batch is a Success: Validation and Qualification

Translating research discoveries to commercialised cell and gene therapy products; asking the right questions as an academic.

Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials

From Concept to Commercialisation: Why the selection of an organisation for a cell and gene therapies can impact your patient outcomes and competitive advantage

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Bev Menner as the company’s new Chief Executive Officer.

New commercial-scale cell and gene therapy manufacturing facility for APAC market supply

Translating innovative cell therapies: What is GMP?

Why Australia should be your choice for CGT development

Unrivalled experience and service from a global leader in cell and gene therapy manufacturing

Services

Helpful Links

Corporate